So far, the experience with IL-6 inhibitors in psoriasis is limited, as other signaling pathways have been successfully investigated as therapeutic targets (i.e., TNF-alpha, IL-23, and IL-17) [8, 36, 38, 104]. The gene discussed is IL6; the disease is psoriasis.